AI-Powered Drug Discovery Summit: MindWalk and Absci CEOs to Join Panel

Dr. Jennifer Bath, President and Chief Executive Officer of bio-native AI company MindWalk Holdings Corp. (NASDAQ: HYFT), is set to join a virtual panel titled "Partnering to Power the New Era of Drug Discovery" at Jones AI Day. Scheduled for Monday, June 15, 2026, at 12:00 p.m. ET, this significant event will feature Dr. Bath alongside representatives from Absci (NASDAQ: ABSI) and a leading AI compute provider. The panel aims to discuss how the convergence of high-performance computing, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discovery.

Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the discussion will delve into AI's role in overcoming challenges such as prolonged screening timelines and historically undruggable targets in drug development. MindWalk emphasizes that the durable asset in biological AI is the enriched context layer, rather than any individual model, and how this layer makes agentic AI trustworthy enough for deployment in regulated workflows. The company's ReefIQ™ biological context layer, powered by HYFT® technology, enriches biological data upon ingestion and connects it across a continuously evolving knowledge representation comprising 660 million biological patterns and 25 billion relationships.

Absci Corporation (NASDAQ: ABSI), another participant in the panel, operates as a clinical-stage biopharmaceutical company leveraging generative AI to advance innovative therapeutics. Its Integrated Drug Creation platform combines advanced AI models with scalable wet-lab technologies to design and validate novel biologic drug candidates. Absci's lead candidate, ABS-201, is currently in Phase 1/2a trials for androgenetic alopecia and is progressing towards a planned Phase 2 trial for endometriosis.

Such panels underscore the transformative potential of AI in drug discovery and development. AI-powered platforms can condense processes that traditionally take years into mere months, while also aiding in the identification of safer and more effective drug candidates. Industry players are seeking competitive advantages by optimizing data flow and enhancing their understanding of biological complexity. MindWalk's "biology-first" approach and Absci's integrated platform hold the potential to accelerate the pace of innovation in this field.

The AI-driven drug discovery market remains a competitive landscape with significant investments and rapid advancements. Analysts have highlighted the long-term potential of AI-focused platforms from companies like Absci, issuing 'buy' recommendations for their stocks. However, companies in this sector often face substantial operating losses and a need for additional capital. Strategic partnerships and technological integration, exemplified by MindWalk and Absci, will be crucial for their future success.

Looking ahead, AI technologies are expected to become even more pervasive in drug discovery and to further optimize clinical trial processes. The more efficient processing and integration of biological data with AI models, in particular, could revolutionize the development of new therapeutic approaches. The topics discussed at the panel will offer key insights into these industry expectations and shape the future direction of the synergy between AI and biotechnology.